P&G POSTS ONLY POINT-PLUS GAIN AS INDEX PLUNGES; ALL COMPONENTS OFF
Executive Summary
P&G POSTS ONLY POINT-PLUS GAIN AS INDEX PLUNGES; ALL COMPONENTS OFF Procter & Gamble (up 1-3/4 to 49-3/8) was the only stock on the 52-issue "F-D-C" Index to gain more than a point as pharmaceutical/diversified stocks followed the market downward. Thompson Medical (up 3/4 to 22), Revlon (up 5/8 to 37-3/4) and Sterling (up 1/8 to 25-1/4) were the only other Diversified stocks to gain ground. Hardest hit were 2-1/8 point decliners Bergen-B (to 22-1/8) and Americal Hospital Supply (to 33-1/4). Overall, only nine of 52 stocks on the index broke even with two stocks unchanged on the week. Losing ground among Pharmaceuticals were Searle (off 5-1/4 to 37-1/2), Schering (down 2 to 35-1/2), and 1-1/2 point losers Lilly (to 61-1/8) and Bolar (to 27-3/8). All other movement on the component was fractional. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth